Literature DB >> 12584046

HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells.

Marcela V Maus1, James L Riley, William W Kwok, Gerald T Nepom, Carl H June.   

Abstract

Current evidence suggests that immunotherapy for cancer or infectious diseases will require the activation of CD4(+) T cells in addition to the activation of cytotoxic CD8(+) T cells. To complement and overcome some of the limitations of dendritic-cell-based vaccines and ex vivo expansion of human T cells, we sought to engineer artificial antigen-presenting cells (aAPCs) for the stimulation of antigen-specific human CD4(+) T cells. We have designed a variety of aAPCs using magnetic beads as a scaffold on which to coat HLA-peptide tetrameric complexes along with costimulatory molecules such as anti-CD28. Here, we tested various forms of conjugation of the tetramers onto beads, characterized the relative concentration of antigen available on the surface of the beads, and evaluated the ability of different types of beads to promote activation of antigen-specific CD4(+) T cells. We find that an indirect coating of HLA-peptide tetramers on beads via an anti-Class II antibody provides specific stimulation of antigen-specific CD4(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12584046     DOI: 10.1016/s1521-6616(02)00017-7

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  21 in total

1.  Controlled major histocompatibility complex-T cell receptor signaling allows efficient generation of functional, antigen-specific CD8+ T cells from embryonic stem cells and thymic progenitors.

Authors:  Jian Lin; Hui Nie; Phillip W Tucker; Krishnendu Roy
Journal:  Tissue Eng Part A       Date:  2010-09       Impact factor: 3.845

Review 2.  Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.

Authors:  D L DiGiusto; L J N Cooper
Journal:  Cytotherapy       Date:  2007       Impact factor: 5.414

3.  Permanent silencing of NKG2A expression for cell-based therapeutics.

Authors:  Constança Figueiredo; Axel Seltsam; Rainer Blasczyk
Journal:  J Mol Med (Berl)       Date:  2008-11-11       Impact factor: 4.599

Review 4.  MHC class II tetramers.

Authors:  Gerald T Nepom
Journal:  J Immunol       Date:  2012-03-15       Impact factor: 5.422

5.  A miRNA181a/NFAT5 axis links impaired T cell tolerance induction with autoimmune type 1 diabetes.

Authors:  Isabelle Serr; Martin G Scherm; Adam M Zahm; Jonathan Schug; Victoria K Flynn; Markus Hippich; Stefanie Kälin; Maike Becker; Peter Achenbach; Alexei Nikolaev; Katharina Gerlach; Nicole Liebsch; Brigitta Loretz; Claus-Michael Lehr; Benedikt Kirchner; Melanie Spornraft; Bettina Haase; James Segars; Christoph Küper; Ralf Palmisano; Ari Waisman; Richard A Willis; Wan-Uk Kim; Benno Weigmann; Klaus H Kaestner; Anette-Gabriele Ziegler; Carolin Daniel
Journal:  Sci Transl Med       Date:  2018-01-03       Impact factor: 17.956

Review 6.  Nanoengineering approaches to the design of artificial antigen-presenting cells.

Authors:  Joel C Sunshine; Jordan J Green
Journal:  Nanomedicine (Lond)       Date:  2013-07       Impact factor: 5.307

Review 7.  Nanoscale artificial antigen presenting cells for cancer immunotherapy.

Authors:  Kelly R Rhodes; Jordan J Green
Journal:  Mol Immunol       Date:  2018-03-07       Impact factor: 4.407

Review 8.  Biomimetic delivery with micro- and nanoparticles.

Authors:  Stephen C Balmert; Steven R Little
Journal:  Adv Mater       Date:  2012-04-23       Impact factor: 30.849

Review 9.  Killer artificial antigen-presenting cells: the synthetic embodiment of a 'guided missile'.

Authors:  Christian Schütz; Mathias Oelke; Jonathan P Schneck; Andreas Mackensen; Martin Fleck
Journal:  Immunotherapy       Date:  2010-07       Impact factor: 4.196

10.  Fabrication of Anisotropic Polymeric Artificial Antigen Presenting Cells for CD8+ T Cell Activation.

Authors:  Elana Ben-Akiva; Kelly R Rhodes; Randall A Meyer; Jordan J Green
Journal:  J Vis Exp       Date:  2018-10-12       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.